Shareholders Foundation, Inc.

Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) Investor Alert: Lawsuit Alleges Misleading Statements

A lawsuit was filed on behalf of investors in Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) shares over alleged securities laws violations. Deadline: July 7, 2015. NYSEMKT:AMPE investors should contact the Shareholders Foundation.

 

San Diego, CA -- (SBWIRE) -- 05/12/2015 -- An investor, who purchased shares of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE), filed a lawsuit in the U.S. District Court for the Central District of California over alleged violations of Federal Securities Laws by Ampio Pharmaceuticals Inc in connection with certain allegedly false and misleading statements made between January 13, 2014 and August 21, 2014.

Investors who purchased shares of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) have certain options and for certain investors are short and strict deadlines running. Deadline: July 7, 2015. NYSEMKT:AMPE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint the plaintiff alleges on behalf of purchasers of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) common shares between January 13, 2014 and August 21, 2014, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the clinical research organization conducting the STEP Study lacked independence, that the trial drug supply for the STEP Study was shipped to clinical sites at lower temperatures than permitted by the drug specifications, and that as a result, of the foregoing, the Company's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

On April 20, 2015 Ampio Pharmaceuticals Inc announced that the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control even though there was a statistically significant reduction in pain compared to baseline for patients receiving Ampion (WOMAC A: p < 0.001). Shares of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) declined to as low as $2.21 per share on May 6, 2015.

Those who purchased shares of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com